The Bill and Melinda Gates Foundation has launched its fourth annual Goalkeepers Report, featuring new data showing how the ripple effects of COVID-19 have stopped 20 years of progress toward the United Nations Sustainable Development Goals.
The report provides the most current global dataset for how the pandemic is affecting progress toward the Global Goals.
It shows that by nearly every indicator, the world has regressed. Because of COVID-19, extreme poverty has increased by 7 percent.
Vaccine coverage, a good proxy measure for how health systems are functioning, is dropping to levels last seen in the 1990s, setting the world back about 25 years in 25 weeks.
Economic damage from COVID-19 is reinforcing inequalities. The pandemic has had a disproportionate impact on women, racial and ethnic minority communities, and people living in extreme poverty. Around the world, women are facing an increased burden from rising demands in total unpaid care work and experiencing the majority of job losses.
- 1 Premier League virus cases drop to 16 as pressure eases
- 2 Covid costs NSE investors Sh200b
- 3 No coronavirus deaths in Kenya today - Health ministry
- 4 HSBC to axe 82 UK branches, cut services in others
In the report, Bill and Melinda Gates call on the world to collaborate on the development of diagnostics, vaccines, and treatment; manufacture tests and doses as quickly as possible; and deliver these tools equitably based on need rather than the ability to pay.
“The response to the COVID-19 pandemic has shown us some of the best of humanity: pathbreaking innovation, heroic acts by frontline workers, and ordinary people doing the best they can for their families, neighbors, and communities,” said Bill and Melinda Gates. “This is a shared global crisis that demands a shared global response.”
The report makes clear that no single country will be able to meet this challenge alone. Any attempts by one country to protect itself while neglecting others will only prolong the hardships caused by the pandemic. Developing and manufacturing vaccines will not end the pandemic quickly unless they are delivered equitably.
According to modeling from Northeastern University, if rich countries buy up the first 2 billion doses of vaccine instead of making sure they are distributed equitably, then almost twice as many people could die from COVID-19.
The International Monetary Fund projects that, despite the USD18 trillion already spent to stimulate economies around the world, the global economy will lose USD12 trillion or more by the end of 2021—the biggest global GDP loss since the end of World War II.
In some countries, spending on emergency stimulus and social protection has prevented worse outcomes. But there are inherent limits to what low- and middle-income countries can do to safeguard their economies, regardless of how effectively those economies have been managed.
Despite these constraints, countries are innovating to meet the challenges. More candidates for vaccines and therapeutics are being developed faster than ever. Pandemic-focused innovations include contact tracing in Vietnam and pooled testing in Ghana, while new or improved digital cash transfer programs are reaching 1.1 billion people in 138 countries.
The Africa Centres for Disease Control and Prevention and dozens of partners launched the African Medical Supplies Platform in June to ensure that countries on the continent have access to affordable, high quality, lifesaving equipment and supplies, many of which are manufactured in Africa.
Bill and Melinda Gates say COVID-19 is a true test for the global community.
“One of the most troubling things about this pandemic is that by disrupting health systems and the global economy, it’s starting to erase the progress people have made toward living healthier, more productive lives,” said Melinda Gates. “Our report highlights actions the world can take to turn things around. Researchers are very close to developing safe, effective coronavirus vaccines, but breakthrough science must be met by breakthrough generosity. We need leaders in government and the pharmaceutical industry to ensure that everyone, regardless of where they live, can access these vaccines. And we’re hopeful that will happen.”